Midatech is developing a new form of cancer therapy based on nanomedicines combining validated chemotherapeutics, targeting molecules and gold nanoparticles. This new composition will enable highly toxic drugs to specifically target tumours, reduce side effects and enhance efficacy.
Midatech will focus on developing nanomedicines that utilise drugs which are near or off-patent to combine physician experience with optimized drug properties creating new composition of matter while mitigating clinical risk.
Midatech website: http://www.midatechgroup.com
